THE RESPONSE TO ANAPLASTIC LYMPHOMA KINASE INHIBITOR IN METASTATIC ANAPLASTIC THYROID CARCINOMA
- Author:
NF AB MUIN
1
;
GF HO
2
Author Information
1. Radiotherapy & Oncology Department, Hospital Canselor Tuanku Muhriz, Faculty of Medicine, Universiti Kebangsaan Malaysia
2. Clinical Oncology Department, University of Malaya Medical Centre, Faculty of Medicine, University of Malaya
- Publication Type:Case Reports
- Keywords:
Anaplastic Thyroid Carcinoma;
ALK Inhibitor;
Ceritinib;
Alectinib;
Tyrosine Kinase Inhibitor
- From:
Brunei International Medical Journal
2022;18():84-88
- CountryBrunei Darussalam
- Language:English
-
Abstract:
Anaplastic thyroid carcinoma is an undifferentiated tumour and lethal. Conventional treatment
has not demonstrated clear therapeutic efficacy in prolonging the survival in metastatic anaplastic thyroid carcinoma. We report a case of a 44-year-old woman who was diagnosed with stage IV anaplastic thyroid carcinoma with positive anaplastic lymphoma kinase-echinoderm microtubule-associated protein-like-4 mutation. She demonstrated a good response to anaplastic lymphoma kinase inhibitors therapy with stable disease status for more than six months. This case report shows clinical efficacy of anaplastic lymphoma kinase inhibitor in a patient with stage IVC anaplastic thyroid carcinoma with positive anaplastic lymphoma kinase mutation.
- Full text:2026072313505441157BIMJ2022-18-84-88.pdf
